Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

SRZN vs ITRM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SRZN Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–1 Matrix Metrics)

SRZN Overall Winner 6-Pillar Tally: SRZN 4 – 1 ITRM (1 Tie) Matrix Metrics: SRZN 6 – 1 ITRM

As of Nov 20, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over Iterum Therapeutics plc Ordinary Share (ITRM) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SRZN carries a Unified Composite Score of 36.0/100 (SELL) at $28.46 (N/M Forward P/E, -485.4% operating margin), whereas ITRM carries 50.5/100 (HOLD) at $0.03 (N/M Forward P/E, -1982.3% operating margin).

  • Composite vs. Pillar Nuance: While ITRM currently prints a higher short-term Unified Composite Score (50.5/100 HOLD vs. SRZN 36.0/100 SELL), SRZN captures the overall institutional head-to-head verdict (6–1 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -1982.3% operating margin) and revenue trajectory (+408.6% vs. -100.0% YoY).
  • Technical & Structure Timing Caution: SRZN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.2); meanwhile ITRM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SRZN vs ITRM
SRZN NASDAQ Head-to-Head Winner
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$28.46
-7.21% 1D
Market Cap $642.7M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.29β · 73% Vol
Unified Composite Score
36.0 / 100 SELL
Tech 15.0 Fund 42.0 Flow 65.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.2 · SMA20: $30.47 · SMA50: $26.93
ITRM NASDAQ
Iterum Therapeutics plc Ordinary Share
Pharmaceutical Preparations
$0.03
-57.39% 1D
Market Cap $3.8M
TTM Revenue $390,000
Forward P/E N/M
Beta / 30D Vol 1.61β · 508% Vol
Unified Composite Score
50.5 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 75.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -23.9%), weak momentum, RSI 26
RSI-14: 25.9 · SMA20: $0.15 · SMA50: $0.23

6-Pillar Scorecard Institutional Category Breakdown (SRZN 4 – 1 ITRM)

Columns: Metric · SRZN · ITRM
1. Valuation Multiples ITRM
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 52.1x 9.6x
2. Growth & Scale SRZN
Revenue Growth (YoY) +408.6% -100.0%
Earnings Growth (YoY) -37.0% +0.0%
TTM Revenue (USD) $11M $390,000
Market Cap $642.7M $3.8M
3. Profitability & Quality SRZN
Gross Margin N/A 29.7%
Operating Margin -485.4% -1982.3%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -62.8% -555.7%
4. Balance Sheet & Cash Flow SRZN
Cash Generation (TTM) -$31M -$19M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $95M Net Cash -555.7% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SRZN
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 72.0% (13th %ile) N/A (N/A)
Put/Call OI Skew 21.00x (Put-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SRZN (6) vs ITRM (1)
Institutional Metric SRZN ITRM Criterion Row Edge
Market Capitalization
Scale
$642.7M $3.8M Larger Scale SRZN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+408.6% -100.0% Higher Growth SRZN
Operating Margin (TTM)
Profitability
-485.4% -1982.3% Higher Margin SRZN
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-62.8% -555.7% Higher ROE SRZN
52-Week Range Position
Momentum
63% ($13–$38) 0% ($0–$1) Stronger Trend SRZN
Beta / 30D Volatility
Risk Regime
1.29β · 73% Vol 1.61β · 508% Vol Lower Realized Risk SRZN
Unified Institutional Score
Composite Signal
36.0 / 100 (SELL) 50.5 / 100 (HOLD) Higher Composite ITRM
Trailing 12M Revenue (USD)
Operating Scale
$11M $390,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 29.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 52.1x EV/Rev N/M PEG · 9.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$31M ($95M Net Cash) -$19M EBITDA (-555.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SRZN +91.23 pp
SRZN: +1.85% · ITRM: -89.38%
3M Horizon SRZN +123.43 pp
SRZN: +33.81% · ITRM: -89.62%
6M Horizon SRZN +207.99 pp
SRZN: +115.78% · ITRM: -92.21%
1Y Horizon SRZN +207.99 pp
SRZN: +115.78% · ITRM: -92.21%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SRZN vs ITRM. Trailing 12-month operating profitability (SRZN -485.4% vs ITRM -1982.3%) and valuation multiples (SRZN N/M vs ITRM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

SRZN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross MarginN/A
Op. Margin-485.4%
ROE / Fwd P/E-62.8% · N/M
ITRM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$390,000
Gross Margin29.7%
Op. Margin-1982.3%
ROE / Fwd P/E-555.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SRZN CONSOLIDATION
41d in phase · OBV NEUTRAL
Current IV 72.0%
IV Percentile 13th %ile
Put/Call OI Skew 21.00x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SRZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ITRM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ITRM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SRZN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $642.7M market capitalization and -485.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ITRM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.8M market capitalization and -1982.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SRZN vs ITRM Key Questions & Quantitative Answers

As of Nov 20, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over Iterum Therapeutics plc Ordinary Share (ITRM) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SRZN carries a Unified Composite Score of 36.0/100 (SELL) at $28.46 (N/M Forward P/E, -485.4% operating margin), whereas ITRM carries 50.5/100 (HOLD) at $0.03 (N/M Forward P/E, -1982.3% operating margin). Composite vs. Pillar Nuance: While ITRM currently prints a higher short-term Unified Composite Score (50.5/100 HOLD vs. SRZN 36.0/100 SELL), SRZN captures the overall institutional head-to-head verdict (6–1 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -1982.3% operating margin) and revenue trajectory (+408.6% vs. -100.0% YoY). Technical & Structure Timing Caution: SRZN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.2); meanwhile ITRM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SRZN leads the Growth & Scale pillar: SRZN posts +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin), compared with ITRM at -100.0% YoY revenue growth and +0.0% YoY earnings growth on $390,000 TTM revenue (29.7% gross margin, -1982.3% operating margin). On trailing 12-month operating scale, SRZN generates $11M in USD-normalized revenue versus $390,000 for ITRM. In operating R&D and SG&A reinvestment, SRZN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ITRM.

ITRM screens cheaper on headline valuation multiples. SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 52.1x EV/Revenue (unreported FCF margin), whereas ITRM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.6x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SRZN (-62.8% ROE) versus ITRM (-555.7% ROE) capital efficiency.

In options market volatility and institutional positioning, SRZN carries 72.0% implied volatility (13th %ile, Compressed (<25th %ile)), a 21.00x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.29β · 73% Vol realized risk). By comparison, ITRM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.61β · 508% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.